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a b s t r a c t
Brivaracetam (BRV), a selective, high-afﬁnity ligand for synaptic vesicle protein 2A, is a new antiepileptic
drug (AED) for adjunctive treatment of focal (partial-onset) seizures in adults with epilepsy. This posthoc analysis was conducted to explore the efﬁcacy of adjunctive BRV in patients with prior levetiracetam
(LEV) exposure and whether changes in efﬁcacy were related to the similar mechanism of action of these
two drugs. Data were pooled from three Phase III studies (NCT00490035; NCT00464269; NCT01261325)
of adults with focal seizures taking 1–2 AEDs who received placebo or BRV 50–200 mg/day without titration over a 12-week treatment period. Patients taking concomitant LEV at enrollment were excluded from
this analysis. Patients were categorized by their status of prior exposure to LEV, carbamazepine (CBZ),
topiramate (TPM), or lamotrigine (LTG), to investigate any consistent trend towards reduced response
in AED-exposed subgroups compared to AED-naïve subgroups, regardless of the mechanism of action.
Study completion rates, percent reduction from baseline in focal seizure frequency over placebo, ≥50%
responder rates, and tolerability were evaluated for each subgroup. A total of 1160 patients were investigated. Study completion rates were similar in the AED-exposed subgroups and AED-naïve subgroups.
In subgroups with (531 patients) or without (629 patients) prior LEV exposure, ≥50% responder rates for
each dose of BRV compared with placebo were generally higher among the LEV-naïve subgroups than
the previously LEV-exposed subgroups. LEV-exposed subgroups receiving BRV doses ≥50 mg/day showed
greater ≥50% responder rates than those receiving placebo. Similar results were observed for CBZ, TPM,
and LTG. Previous treatment failure with commonly prescribed AEDs (LEV, CBZ, TPM, or LTG) is associated
with a reduced response to BRV irrespective of the mechanism of action. Hence, this post-hoc analysis
indicates that previous treatment failure with LEV does not preclude the use of BRV in patients with
epilepsy.
© 2017 UCB Pharma. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Brivaracetam (BRV) is a new antiepileptic drug (AED) derived
from a targeted drug discovery program (Klitgaard et al., 2016).
BRV is a selective, high-afﬁnity ligand for synaptic vesicle protein 2A (SV2A) (Gillard et al., 2011). Its binding afﬁnity with SV2A
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is higher than that of levetiracetam (LEV), another SV2A ligand
(Gillard et al., 2011). The tolerability and efﬁcacy of adjunctive BRV
in patients with drug-resistant focal (partial-onset) seizures with
or without secondary generalization have been investigated and
demonstrated in three pivotal Phase III studies (Biton et al., 2014;
Klein et al., 2015a; Rheims and Ryvlin, 2014). One recent metaanalysis (Ma et al., 2015) identiﬁed ﬁve randomized, controlled
trials of BRV in the treatment of drug-resistant focal epilepsies and
included a total of 1639 patients. This meta-analysis demonstrated
a statistically signiﬁcant improvement in seizure control compared
with placebo, and favorable tolerability of therapeutic doses of
BRV (50–200 mg/day) as an adjunctive treatment for drug-resistant
focal epilepsy.

http://dx.doi.org/10.1016/j.eplepsyres.2017.02.007
0920-1211/© 2017 UCB Pharma. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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Approximately one-third of individuals with epilepsy have inadequate seizure control despite the use of appropriate AEDs (Kwan
and Brodie, 2000b). In addition, treatment in patients with epilepsy
is often complicated by the unpredictability of the efﬁcacy of any
given AED. This uncertainty of response, particularly in patients
with drug-resistant seizures, may obfuscate the use of any newly
developed AED (Kwan et al., 2010). This is particularly important
if the newly developed AED has similarities to an already existing AED. For example, it is helpful to know whether failure of a
currently available AED, such as LEV, precludes the prescription
of a newly developed AED (i.e. BRV) that also targets one of the
same molecular sites of action. It is noteworthy that BRV differs
signiﬁcantly from LEV by its selective, high afﬁnity, and differential
interaction with SV2A, as well as a higher lipophilicity, correlating
with a more rapid brain penetration in preclinical studies (Klitgaard
et al., 2016). BRV also differs from LEV by neither inhibiting the
␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor (Margineanu and Klitgaard, 2002; Rigo et al., 2004) nor
the high voltage-activated calcium channels at therapeutically relevant concentrations (Klitgaard et al., 2016; Niespodziany et al.,
2015; Pisani et al., 2004). In a post-hoc analysis of study N01358,
efﬁcacy with adjunctive BRV was demonstrated in subgroups with
prior LEV exposure and also in LEV-naïve patients, but the response
appeared to be greater in the LEV-naïve population (Klein et al.,
2015a). The aim of the current post-hoc analysis was to explore
the efﬁcacy of adjunctive BRV in patients with or without prior LEV
exposure in a larger patient population pooled from three Phase
III studies, and to determine whether any observed trend towards
reduced efﬁcacy in LEV-exposed patients compared with LEV-naïve
patients was related to mechanism of action. Some other commonly prescribed AEDs [carbamazepine (CBZ), lamotrigine (LTG),
and topiramate (TPM)] were also investigated to see whether prior
exposure to these drugs was related to BRV efﬁcacy. Tolerability
data were evaluated for each subgroup. These data may be helpful
in the decision-making process when considering the use of BRV
for patients who have previously failed other AEDs.
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having been exposed to that particular AED” and AED-exposed as
“having been exposed to that particular AED” (during the past 5
years for studies N01252 and N01253, and during the patient’s
lifetime before study entry for study N01358). For AED-exposed
patients, that speciﬁc AED had to have been discontinued at least
90 days prior to enrollment in the Phase III study. Demographic and
baseline epilepsy characteristics, and the number (%) of patients
who completed the study, were summarized for each subgroup.
The efﬁcacy population comprised all randomized patients who
received at least one dose of study drug and had at least one postbaseline seizure diary entry. Percent reduction from baseline in
focal seizure frequency over placebo, and ≥50% responder rates,
were evaluated for each subgroup of patients. A further subgroup
analysis was conducted for ≥50% responder rate based on the number of prior AEDs (≤2, 3–5, and ≥6). This subgroup analysis was
conducted on a modiﬁed efﬁcacy population that included patients
taking concomitant LEV. In this analysis, a prior AED was deﬁned as
any AED that was taken previously and/or concomitantly at study
entry.
Treatment group comparisons (BRV ≥50 mg/day vs. placebo) for
≥50% responder rates were based on a logistic regression model
with ≥50% responder rate as the outcome, and with effects for treatment, study, and log-transformed baseline focal seizure frequency
as a continuous covariate. The logistic regression model was used
to examine the relationship between the ≥50% responder rate and
a set of predictor variables. The model used a logit transformation
of the outcome, which is the log of the odds or the ratio of the probability of the outcome (yes for ≥50% response) to the probability
of no outcome (no for ≥50% response). All statistical analyses were
exploratory.
Details of the study population, efﬁcacy assessments, safety and
tolerability assessments, and ethical issues are explained in the previous Phase III studies (Biton et al., 2014; Klein et al., 2015a; Rheims
and Ryvlin, 2014).

3. Results
2. Methods
This is a post-hoc analysis of data pooled from three Phase III
studies (N01252, NCT00490035; N01253, NCT00464269; N01358,
NCT01261325) (Biton et al., 2014; Klein et al., 2015a; Rheims and
Ryvlin, 2014). All patients included in this analysis were randomized to BRV 50, 100, and 200 mg per day or placebo. Patients who
were on concomitant LEV at the time of enrollment were excluded
from this analysis. Patients were categorized by their status of prior
exposure to LEV, CBZ, TPM, or LTG. We deﬁned AED-naïve as “never

A total of 1160 patients were included in this analysis. Overall, 531 patients had previously been exposed to LEV and 629
were LEV-naïve. Demographic and baseline epilepsy characteristics are shown in Table 1. Demographic characteristics were similar
between the AED-exposed and AED-naïve subgroups. However, the
proportion of patients who had previously failed at least 5 AEDs
was higher among previously LEV-, CBZ-, TPM-, and LTG-exposed
subgroups (61–69%) than among subgroups who had never taken
those particular AEDs (13–17%).

Table 1
Demographic and baseline epilepsy characteristics, by prior exposure to levetiracetam, carbamazepine, topiramate, or lamotrigine (efﬁcacy population).
Levetiracetam

Carbamazepine

Topiramate

Lamotrigine

Exposed
(n = 578)

Naïve
(n = 743)

Exposed
(n = 424)

Naïve
(n = 339)

Exposed
(n = 428)

Naïve
(n = 696)

Exposed
(n = 349)

Naïve
(n = 639)

Age, mean (SD), years
Female, n (%)

39.8 (13.3)
318 (55.0)

36.9 (12.6)
341 (45.9)

39.6 (13.5)
229 (54.0)

37.4 (14.2)
165 (48.7)

38.5 (12.8)
232 (54.2)

38.3 (13.4)
306 (44.0)

39.7 (13.2)
188 (53.9)

38.0 (13.1)
282 (44.1)

No. of prior AEDs, n (%)
0–1
2–4
≥5

29 (5.0)
176 (30.4)
373 (64.5)

304 (40.9)
343 (46.2)
96 (12.9)

24 (5.7)
140 (33.0)
260 (61.3)

136 (40.1)
145 (42.8)
58 (17.1)

11 (2.6)
123 (28.7)
294 (68.7)

280 (40.2)
310 (44.5)
106 (15.2)

5 (1.4)
107 (30.7)
237 (67.9)

263 (41.2)
280 (43.8)
96 (15.0)

Baseline focal seizure
frequency/28 days, median (Q1, Q3)

11.0 (6.4, 26.8) 7.9a (5.0, 15.9) 9.6 (5.8, 24.2)

8.3 (5.5, 19.2) 9.7 (5.8, 24.5)

8.5b (5.3, 18.8) 11.3 (6.1, 25.8) 8.0c (5.1, 16.9)

The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
a
n = 742, b n = 695, c n = 638; patients without baseline seizure frequency were excluded.
AED, antiepileptic drug; Q1, ﬁrst quartile; Q3, third quartile; SD, standard deviation.

72

A.A. Asadi-Pooya et al. / Epilepsy Research 131 (2017) 70–75

Fig. 1. ≥50% responder rates in patients treated with brivaracetam, with or without prior levetiracetam (A), carbamazepine (B), topiramate (C) or lamotrigine (D) exposure
(efﬁcacy population).
p-values (BRV vs. placebo) are derived from a logistic regression model with effects for treatment, study, and log-transformed baseline focal seizure frequency as a continuous
covariate. All p-values are exploratory. The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline
seizure diary entry; patients taking concomitant LEV were excluded.
BRV, brivaracetam; CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; TPM, topiramate.

Numbers of patients enrolled, study completion (retention)
rates, and percent reduction from baseline in focal seizure frequency over placebo for each subgroup of patients are shown in
Tables 2–5, and ≥50% responder rates for each subgroup of patients
are shown in Fig. 1.
Retention rates, which are predominantly a reﬂection of tolerability, were similar in the AED-exposed and AED-naïve subgroups.
The 12-week retention rates during the study period were >84% in
all subgroups (all doses and all drugs) (Tables 2–5).
Percent reduction from baseline in focal seizure frequency over
placebo was numerically greater in BRV-treated, LEV-naïve subgroups than in BRV-treated, LEV-exposed subgroups (Table 2). A
similar pattern was seen for subgroups with and without prior
exposure to CBZ, TPM, and LTG (Tables 3–5 ).
The ≥50% responder rates for BRV compared with placebo were
higher among the LEV-naïve subgroups than the LEV-exposed subgroups (Fig. 1A). However, LEV-exposed subgroups receiving BRV
doses ≥50 mg/day showed higher ≥50% responder rates than corresponding placebo subgroups. Similar results were observed in
subgroups with or without prior CBZ, TPM, and LTG exposure,

although the differences between the corresponding AED-exposed
and AED-naïve subgroups for BRV versus placebo were less marked
for CBZ and LTG (Fig. 1B–D).
Responder rates for subgroups of patients with ≤2, 3−5, and
≥6 prior AED exposures are shown in Table 6. When the number
of prior AEDs was 3–5, the LEV-naïve subgroup showed a greater
response with BRV, compared with placebo, than the LEV-exposed
subgroup. A similar trend was observed with other AEDs (i.e. CBZ,
TPM, and LTG). In subgroups with ≤2 prior AEDs, the number of
patients was too small for statistical analysis. No clear pattern was
seen in subgroups with ≥6 prior AED exposures.

4. Discussion
BRV is a new AED that has demonstrated efﬁcacy as an adjunctive treatment for adults with focal epilepsies and has been shown
to be well tolerated (Biton et al., 2014; Klein et al., 2015a; Kwan
et al., 2014; Rheims and Ryvlin, 2014). A previous post-hoc analysis indicated that adjunctive BRV was effective both in subgroups
of patients with prior exposure to LEV and in those who were

A.A. Asadi-Pooya et al. / Epilepsy Research 131 (2017) 70–75
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Table 2
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior levetiracetam (LEV) exposure (efﬁcacy population).
Placebo

BRV 50 mg/day

BRV 100 mg/day

BRV 200 mg/day

BRV ≥50 mg/day

LEV- exposed

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

191
184 (96.3)
–

48
43 (89.6)
5.1

158
141 (89.2)
17.3

134
119 (88.8)
20.3

340
303 (89.1)
12.8

LEV- naïve

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

227
212 (93.4)
–

113
104 (92.0)
26.1

174
158 (90.8)
30.0

115
106 (92.2)
27.3

402
368 (91.5)
28.7

The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
Table 3
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior carbamazepine (CBZ) exposure (efﬁcacy population).
Placebo

BRV 50 mg/day

BRV 100 mg/day

BRV 200 mg/day

BRV ≥50 mg/day

CBZ- exposed

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

143
137 (95.8)
–

34
31 (91.2)
5.4

113
100 (88.5)
23.1

98
88 (89.8)
19.2

245
219 (89.4)
15.0

CBZ- naïve

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

103
96 (93.2)
–

46
39 (84.8)
23.3

89
81 (91.0)
30.3

58
51 (87.9)
17.7

193
171 (88.6)
26.4

The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
Table 4
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior topiramate (TPM) exposure (efﬁcacy population).
Placebo

BRV 50 mg/day

BRV 100 mg/day

BRV 200 mg/day

BRV ≥50 mg/day

TPM- exposed

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

123
120 (97.6)
–

38
35 (92.1)
13.1

115
99 (86.1)
17.9

104
90 (86.5)
18.2

257
224 (87.2)
13.1

TPM- naïve

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

212
197 (92.9)
–

113
104 (92.0)
24.4

170
158 (92.9)
29.6

117
108 (92.3)
31.3

400
370 (92.5)
28.6

The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
Table 5
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior lamotrigine (LTG) exposure (efﬁcacy population).
Placebo

BRV 50 mg/day

BRV 100 mg/day

BRV 200 mg/day

BRV ≥50 mg/day

LTG- exposed

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

105
102 (97.1)
–

27
24 (88.9)
1.8

97
83 (85.6)
22.5

82
74 (90.2)
24.0

206
181 (87.9)
13.1

LTG- naïve

Number of patients
Number of patients who completed the study (%)
Percent reduction from baseline in focal seizure
frequency over placebo

202
190 (94.1)
–

96
90 (93.8)
28.0

149
139 (93.3)
30.6

106
96 (90.6)
28.5

351
325 (92.6)
29.1

The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.

LEV-naïve, although the effect appeared to be greater in the LEVnaïve population (Klein et al., 2015a). In the current post-hoc
analysis, we investigated whether prior exposure to – and failure
of – speciﬁc, commonly used AEDs (i.e. LEV, CBZ, TPM, or LTG) is a
marker for lack of response to BRV in patients with drug-resistant
focal epilepsy, a hypothesis that was not conﬁrmed by the results.

AED treatment in patients with epilepsy is often complicated by
many factors, including the unpredictability of efﬁcacy (Kwan et al.,
2010). It has been observed that, if the ﬁrst appropriately chosen
AED is not efﬁcacious in controlling seizures, the outcome with
respect to seizure control is less favorable with the next prescribed
AED (Kwan and Brodie, 2000a). In a cohort of 478 patients who
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Table 6
≥50% responder rates, by prior AED exposure and number of prior AEDs (modiﬁed efﬁcacy population).
Number of prior AEDs
≤2

≥6

3–5

Placebo

BRV ≥50 mg/day

Placebo

BRV ≥50 mg/day

Placebo

BRV ≥50 mg/day

LEV-exposed

Number of patients
≥50% responder rate, n (%)

15
3 (20.0)

14
7 (50.0)
p = 0.128

61
15 (24.6)

105
37 (35.2)
p = 0.224

115
16 (13.9)

221
58 (26.2)
p = 0.010

LEV-naïve

Number of patients
≥50% responder rate, n (%)

94
23 (24.5)

180
84 (46.7)
p < 0.001

106
23 (21.7)

178
75 (42.1)
p < 0.001

27
5 (18.5)

44
19 (43.2)
p = 0.088

CBZ-exposed

Number of patients
≥50% responder rate, n (%)

12
4 (33.3)

20
13 (65.0)
p = 0.034

56
16 (28.6)

94
39 (41.5)
p = 0.099

82
10 (12.2)

153
46 (30.1)
p = 0.007

CBZ-naïve

Number of patients
≥50% responder rate, n (%)

54
14 (25.9)

89
41 (46.1)
p = 0.030

52
8 (15.4)

90
32 (35.6)
p = 0.011

18
3 (16.7)

40
11 (27.5)
p = 0.291

TPM-exposed

Number of patients
≥50% responder rate, n (%)

5
4 (80.0)

11
4 (36.4)
p = 0.150

44
13 (29.5)

82
31 (37.8)
p = 0.652

82
12 (14.6)

182
51 (28.0)
p = 0.025

TPM-naïve

Number of patients
≥50% responder rate, n (%)

92
19 (20.7)

180
79 (43.9)
p < 0.001

108
23 (21.3)

197
74 (37.6)
p = 0.003

40
6 (15.0)

62
18 (29.0)
p = 0.058

LTG-exposed

Number of patients
≥50% responder rate, n (%)

10
0 (0)

12
6 (50.0)

33
5 (15.2)

53
20 (37.7)
p = 0.054

71
13 (18.3)

157
46 (29.3)
p = 0.109

LTG-naïve

Number of patients
≥50% responder rate, n (%)

84
20 (23.8)

160
73 (45.6)
p = 0.001

109
22 (20.2)

162
61 (37.7)
p = 0.003

29
3 (10.3)

56
17 (30.4)
p = 0.045

All p-values are exploratory. The modiﬁed efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline
seizure diary entry; patients taking concomitant LEV were included.
AED, antiepileptic drug; BRV, brivaracetam; CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; TPM, topiramate.

received newly administered AED treatments in a single epilepsy
clinic (Schiller and Najjar, 2008), the response to newly administered AEDs was highly dependent on the past treatment history.
Seizure freedom rates decreased from 61.8% for the ﬁrst AED to
41.7%, 16.6%, and 0% after 1, 2–5, and 6–7 prior AED failures, respectively. In the current study, we observed that BRV, compared with
placebo, is more efﬁcacious in AED-naïve subgroups than in those
who have previously been exposed to any of the particular AEDs
tested (i.e. LEV, CBZ, TPM, and LTG). In other words, exposure
to prior AEDs can predict a reduced response to BRV. It is likely
that mechanism of action does not play a major role in this phenomenon, as we observed similar trends with prior exposure to
AEDs with different mechanisms of action. We also did not see a
consistent pattern of response in subgroups of patients who had
previously been exposed to ≥6 AEDs. Because patients with ≥6
prior AED failures are highly unlikely to respond to the next AED,
this may be a sufﬁcient reason to exclude this subgroup from the
design of future AED trials.
There are various factors that may contribute to the reduced efﬁcacy observed in different patient populations. Genetic variations
may explain some of the inter-individual variability in response to
AEDs among patients (Franco and Perucca, 2015; Shaheen et al.,
2014). The number of previously tried and failed AEDs, which is
indicative of drug resistance and severity of epilepsy, may also
explain reduced drug responses observed among patients with
refractory epilepsy (Klein et al., 2015b; Schiller and Najjar, 2008;
Voll et al., 2015). Another plausible mechanism of drug resistance
is the overexpression of multidrug efﬂux transporters, such as
P-glycoprotein (P-gp), which would result in lower interstitial levels of AEDs surrounding the epileptogenic tissue (Loscher, 2005;
Schmidt and Loscher, 2005; Sisodiya et al., 2002). Animal and
human studies support the multidrug transporter hypothesis of

multidrug-resistant epilepsy (Asadi-Pooya et al., 2013; Lazarowski
and Czornyj, 2011).
Despite the observed reduced efﬁcacy of BRV in AED-exposed
subgroups compared to AED-naïve subgroups, BRV was more
efﬁcacious when compared with placebo in the AED-exposed subgroups. This observation was consistent for all the investigated
prior AEDs. Therefore, BRV was efﬁcacious for the treatment of focal
epilepsies even in patients who had been previously exposed to
and failed other commonly prescribed AEDs. This is an important
ﬁnding and offers promise for patients with multidrug-resistant
epileptic seizures.
With respect to BRV tolerability, we observed that retention
rates were reasonably high (84.8–93.8%) in all dose groups. In several previous studies, including the original studies for the current
analysis, BRV has demonstrated a good safety and tolerability proﬁle (Biton et al., 2014; Klein et al., 2015a; Rheims and Ryvlin, 2014).
In a small, open-label, prospective, exploratory study of 29 patients
with epilepsy switching from LEV to BRV (Yates et al., 2015), nonpsychotic behavioral adverse events were evaluated. At the end
of the treatment period, 93.1% of patients that switched to BRV
had clinically meaningful reductions in behavioral adverse events.
Mean change from baseline to Week 12 in Patient-Weighted Quality of Life in Epilepsy Inventory-Form-31 (QOLIE-31-P) total score
was 12.1, indicating improved health-related quality of life. These
data suggest that BRV may have a better proﬁle with respect to
behavioral adverse events compared with LEV (Yates et al., 2015).
As this was a post-hoc study, the results of our analysis should
be viewed as exploratory and require conﬁrmation by prospective
studies. Furthermore, all p-values in this study should be considered in the context of an exploratory analysis. In addition, the
numbers of patients in some of the subgroups were too small for
valid statistical analysis.
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In conclusion, while prior exposure to commonly prescribed
AEDs (LEV, CBZ, TPM, and LTG) is associated with a reduced
response to BRV, this effect is seen irrespective of the mechanism
of action. This is consistent with the previous studies cited above,
showing that the likelihood of response to any AED decreases as
the number of prior AEDs increases. This post-hoc analysis therefore indicates that previous treatment failure with LEV does not
preclude the use of BRV.
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